Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530.

Silvia L LocatelliGiuseppa CaredduSimone SerioFrancesca M ConsonniAkihiro MaedaSrikant ViswanadhaSwaroop VakkalankaLuca CastagnaArmando SantoroPaola AllavenaAntonio SicaCarmelo Carlo-Stella

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

Our results support PI3Kδ/γ inhibition as a novel therapeutic strategy that targets both malignant cells and the TME to treat patients with Hodgkin lymphoma.

Keyphrases

hodgkin lymphoma
induced apoptosis
cell cycle arrest
signaling pathway
cell therapy
oxidative stress
mesenchymal stem cells
bone marrow
drug delivery
cell proliferation